Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jul 6, 2016

Keywords

ClinConnect Summary

This clinical trial, called MELBASE, is focused on studying advanced melanoma, which is a serious type of skin cancer. The goal is to gather important information about patients with different stages of melanoma, particularly those who can have their tumors surgically removed (resectable stage II or III) and those with more advanced or inoperable melanoma (unresectable stage III or IV). By collecting data over 10 years, researchers hope to learn more about the disease, including new ways to predict how patients will respond to treatments, the overall quality of life for patients, and the costs associated with their care.

To join the trial, patients must be at least 18 years old and have a confirmed diagnosis of melanoma that fits specific criteria. For instance, those with resectable stage II or III melanoma who haven’t received prior systemic treatments are eligible, as well as those with advanced, unresectable melanoma. Participants can expect regular evaluations and monitoring throughout the study, contributing to a better understanding of melanoma and potentially helping to improve future treatments. It's important to note that patients who have other specific conditions or types of melanoma may not qualify for this trial.

Gender

ALL

Eligibility criteria

• • 1. Cohort Patients with Resectable stage II or III
• Inclusion Criteria:
• • Patients diagnosed with resectable stage IIA/IIB/IIC or III melanoma, confirmed by histological exam.
• • Naïve of systemic treatment for resectable stage II or III. Whose metastatic tumoral material can be collected by the Biological Resource Centers (optional criteria).
• • Aged ≥ 18 years. Consenting to participate (signed informed consent).
• Exclusion Criteria:
• • Patients refusal. Choroid melanoma. Resectable stage 1 melanoma. Stage 4, unresectable primitive or unresectable stage 3 melanoma. Patients under guardianship and under trusteeship.
• 2. Cohort patients with Unresectable stage III or stage IV (resectable or not) or unresectable primary:
• Inclusion Criteria:
• • Patients diagnosed with an advanced melanoma, confirmed by histological exam. Unresectable primitive or unresectable stage III or stage IV (resectable or not) melanoma ; or patients treated by neoadjuvant treatment (exceptional) Naïve of systemic treatment for unresectable primitive or unresectable stage III or stage IV (resectable or not) melanoma, except adjuvant treatment.
• • Whose metastatic tumoral material can be collected by the Biological Resource Centers (optional criteria).
• • Aged ≥ 18 years. Consenting to participate (signed informed consent).
• Exclusion Criteria:
• • Resectable stage 1, 2 or 3 melanoma. Patients refusal. Choroid melanoma. Patients under guardianship and under trusteeship.